Compare Coursera Inc (COUR) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Illumina, Inc. — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 29.9× Coursera Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Illumina, Inc. for 83 Days on average.
| COUR | ILMN | |
|---|---|---|
Market Cap | $1.35B | $40.43B |
Volume | 5,442,629 | 2,948,626 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $293.69 |
52-Week Low | $4.64 | $91.00 |
Typical Hold Time | 47 Days | 83 Days |
Enterprise Value | $606.18M | $41.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.27, up 2.93% with a bearish technical signal despite recent earnings beats. Revenue growth is solid (2025: $758M, 2026: $885M projected) but profitability remains negative with a -15.39% net margin. Analyst consensus is bullish with a $7.40 price target (52.94% buy ratings), while institutional activity shows mixed positioning amid Project Helix AI platform developments.
The stock offers upside potential from AI-driven growth and margin improvements, but faces execution risks on profitability and integration costs. High RSI near 82 suggests overbought conditions, while persistent net losses and competitive pressures in edtech warrant caution for near-term volatility.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
